A recently created services arm at drug-discovery firm Galapagos will help Novartis Pharmaceuticals UK develop and conduct functional assays in primary human cells in an undisclosed disease area, the company said this week.

Under the terms of the agreement, the services division, called Galádeno, will use its SilenceSelect gene knockdown platform to design a research program for Novartis. SilenceSelect is based on Galádeno's collection of adenoviruses with human gene sequences that knock down more than 4,000 human proteins by producing siRNA in human cells.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.

In Science this week: in vitro generation of human reproductive cells, and more.